Effects of the strong CYP3A4 and P-glycoprotein inhibitor itraconazole on the pharmacokinetics of oral and intranasal zavegepant

被引：0
|
作者：
Bhardwaj, R. [1 ]
Malatesta, J. K. [2 ]
Stringfellow, J. [3 ]
Madonia, J. [4 ]
Anderson, M. [4 ]
Stock, D. A. [4 ]
Morris, B. A. [4 ]
Coric, V [5 ]
Croop, R. [5 ]
Bertz, R. [4 ]
机构：
[1] Certara Strateg Consulting, Integrated Drug Dev, Princeton, NJ USA
[2] Certara USA, Princeton, NJ USA
[3] Navitas Data Sci, Pottstown, PA USA
[4] Biohaven Pharmaceut, New Haven, CT USA
[5] Biohaven Pharmaceut Holding Co Ltd, New Haven, CT USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-163
引用
收藏
页码：140 / 141
页数：2
相关论文
共 50 条
  • [1] Effects of the Strong CYP3A4 and P-glycoprotein Inhibitor Itraconazole on the Pharmacokinetics of Oral and Intranasal Zavegepant
    Bhardwaj, Rajinder
    Malatesta, Jo Ann
    Stringfellow, Joseph
    Madonia, Jennifer
    Anderson, Matt
    Morris, Beth
    Coric, Vladimir
    Croop, Robert
    Bertz, Richard
    NEUROLOGY, 2023, 100 (17)
  • [2] Effects of Silibinin, Inhibitor of CYP3A4 and P-Glycoprotein in vitro, on the Pharmacokinetics of Paclitaxel after Oral and Intravenous Administration in Rats
    Lee, Chong-Ki
    Choi, Jun-Shik
    PHARMACOLOGY, 2010, 85 (06) : 350 - 356
  • [3] Effects of clarithromycin on the pharmacokinetics of tacrolimus and expression of CYP3A4 and P-glycoprotein in rats
    Wen, Jinhua
    ChenYang, Menghua
    Zhao, Menghua
    Hu, Weiqiang
    Xiao, Yu Wei
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 (04) : 843 - 848
  • [4] Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole
    Kari T. Kivistö
    Jun-Sheng Wang
    Janne T. Backman
    Leena Nyman
    Päivi Taavitsainen
    Markku Anttila
    Pertti J. Neuvonen
    European Journal of Clinical Pharmacology, 2001, 57 : 37 - 42
  • [5] Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole
    Kivistö, KT
    Wang, JS
    Backman, JT
    Nyman, L
    Taavitsainen, P
    Anttila, M
    Neuvonen, PJ
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (01) : 37 - 42
  • [6] Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone
    Lee, Lucy
    Thoolen, Martin
    Ma, Jiyuan
    Kaushik, Diksha
    Golden, Lee
    Kong, Ronald
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (12): : 1283 - 1290
  • [7] Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats
    Li, C.
    Lee, M. Y.
    Choi, J. S.
    PHARMAZIE, 2010, 65 (07): : 510 - 514
  • [8] The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4
    Groenendaal, Dorien
    Strabach, Gregory
    Garcia-Hernandez, Alberto
    Kadokura, Takeshi
    Heeringa, Marten
    Mol, Roelof
    Eltink, Charlotte
    Onkels, Hartmut
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 440 - 449
  • [9] Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach
    Ito, K
    Kusuhara, H
    Sugiyama, Y
    PHARMACEUTICAL RESEARCH, 1999, 16 (02) : 225 - 231
  • [10] Effects of Intestinal CYP3A4 and P-Glycoprotein on Oral Drug Absorption—Theoretical Approach
    Kiyomi Ito
    Hiroyuki Kusuhara
    Yuichi Sugiyama
    Pharmaceutical Research, 1999, 16 : 225 - 231
12345